View from ESMO: iTeos data keep TIGIT alive, for now

iTeos has delivered another Phase II win for cancer immunotherapy target TIGIT, but with the readout comes some of the same questions and concerns that have contributed to the mechanism’s past failures to translate to Phase III success.

iTeos Therapeutics Inc. (NASDAQ:ITOS) reported at the ESMO Congress in Barcelona that first-line treatment with its Fc-enabled TIGIT blocker belrestotug plus PD-1 mAb Jemperli dostarlimab more than doubled the objective response rate over Jemperli alone in patients with PD-L1-high non-small cell lung cancer (NSCLC). The company reported an overall response rate of about 60% for each of the three doses tested in the Phase II GALAXIES Lung-201 study, compared with a confirmed ORR of 28% in the Jemperli arm...